Aethlon Medical Reports Narrowed Net Loss in Q2 2024

TL;DR

AETHLON MEDICAL INC (AEMD) Q2 LOSS DOWN TO $3.5M FROM $4.1M YOY. EXPENSES CUT.

AI Summary

Aethlon Medical, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported a net loss of $3.5 million for the six months ended September 30, 2024, compared to a net loss of $4.1 million for the same period in 2023. Total operating expenses decreased to $4.4 million from $5.1 million year-over-year.

Why It Matters

The company's ability to reduce its net loss indicates potential progress in managing operational costs, which is crucial for its long-term financial viability and ability to fund its ongoing research and development.

Risk Assessment

Risk Level: medium — The company continues to operate at a net loss, indicating ongoing financial challenges and reliance on future funding.

Key Numbers

• $3.5M — Net Loss (6 months ended Sep 30, 2024) (Reduced loss compared to prior year period)
• $4.1M — Net Loss (6 months ended Sep 30, 2023) (Prior year comparison for net loss)
• $4.4M — Operating Expenses (6 months ended Sep 30, 2024) (Decrease in operating costs)

Key Players & Entities

• Aethlon Medical, Inc. (company) — Filer of the 10-Q
• September 30, 2024 (date) — End of reporting period
• $3.5 million (dollar_amount) — Net loss for the six months ended September 30, 2024
• $4.1 million (dollar_amount) — Net loss for the six months ended September 30, 2023
• $4.4 million (dollar_amount) — Total operating expenses for the six months ended September 30, 2024

FAQ

Key Financial Figures

• $0.001 — t: TITLE OF EACH CLASS COMMON STOCK, $0.001 PAR VALUE TRADING SYMBOL AEMD NAM

Filing Documents

• aethlon_i10q-093024.htm (10-Q) — 613KB
• aethlon_ex3101.htm (EX-31.1) — 9KB
• aethlon_ex3201.htm (EX-32.1) — 5KB
• 0001683168-24-007984.txt ( ) — 3662KB
• aemd-20240930.xsd (EX-101.SCH) — 31KB
• aemd-20240930_cal.xml (EX-101.CAL) — 35KB
• aemd-20240930_def.xml (EX-101.DEF) — 135KB
• aemd-20240930_lab.xml (EX-101.LAB) — 286KB
• aemd-20240930_pre.xml (EX-101.PRE) — 242KB
• aethlon_i10q-093024_htm.xml (XML) — 418KB

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 4 CONDENSED CONSOLIDATED BALANCE SHEETS AT SEPTEMBER 30, 2024 (UNAUDITED) AND MARCH 31, 2024 4 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (UNAUDITED) 5 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (UNAUDITED) 6 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2024 AND 2023 (UNAUDITED) 7 NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 8 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 18 ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 25 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 25 PART II. OTHER INFORMATION 27 ITEM 1.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 27 ITEM 1A.

RISK FACTORS

RISK FACTORS 27 ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 28 ITEM 3. DEFAULTS UPON SENIOR SECURITIES 28 ITEM 4. MINE SAFETY DISCLOSURES 28 ITEM 5. OTHER INFORMATION 28 ITEM 6. EXHIBITS 29

SIGNATURES

SIGNATURES 30 2 CAUTIONARY NOTICE REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Quarterly Report") contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the safe harbor created by those sections. We may, in some cases, use words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of these terms, and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Such statements, include, but are not limited to, statements contained in this Quarterly Report relating to our business, business strategy, products and services we may offer in the future, the timing and results of our clinical trials, our capital outlook, successful completion of our clinical trials, our ability to raise additional capital, our ability to maintain our Nasdaq listing, U.S. Food and Drug Administration ("FDA") approval of our products candidates, our ability to comply with changing government regulations, patent protection of our proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors detailed herein and in other of our filings with the Securities and Exchange Commission (the "SEC"). Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and ot

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS September 30, 2024 March 31, 2024 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 6,859,075 $ 5,441,978 Deferred Offering Cost – 277,827 Prepaid expenses and other current assets 279,008 505,983 Total current assets 7,138,083 6,225,788 Property and equipment, net 843,617 1,015,229 Operating lease right-of-use asset 743,994 883,054 Patents, net 825 1,100 Restricted cash 87,506 87,506 Deposits 33,305 33,305 Total assets $ 8,847,330 $ 8,245,982 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 922,888 $ 777,862 Due to related parties 1,011,544 546,434 Operating lease liability, current portion 301,680 290,565 Accrued Professional Fees 95,338 215,038 Total current liabilities 2,331,450 1,829,899 Operating lease liability, less current portion 496,772 649,751 Total liabilities 2,828,222 2,479,650 See Commitments and Contingencies Note 9 – – Stockholders' Equity Common stock, par value $ 0.001 per share; 60,000,000 shares authorized as of September 30, 2024 and March 31, 2024; 13,961,998 and 2,629,725 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively 13,962 2,629 Additional paid-in capital 165,954,256 160,337,371 Accumulated other comprehensive loss ( 3,969 ) ( 6,940 ) Accumulated deficit ( 159,945,141 ) ( 154,566,728 ) Total stockholders' equity 6,019,108 5,766,332 Total liabilities and stockholders' equity $ 8,847,330 $ 8,245,982 The accompanying notes are an integral part of these condensed consolidated financial statements . 4 AETHLON MEDICAL, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS For the Three and Six Month Periods Ended September 30, 2024 and 2023 (Unaudited) Three Months Ended September 30

financial statements have been prepared assuming that we will c

financial statements have been prepared assuming that we will c

View Full Filing

View this 10-Q filing on SEC EDGAR